Canadian Natural Resources Ltd. vs Medpace Holdings Inc — how do they compare? Canadian Natural Resources Ltd. trades at $42.8 (market cap $88.15B), while Medpace Holdings Inc trades at $539.2 (market cap $15.31B). The key difference: Canadian Natural Resources Ltd. is far larger — about 5.8× Medpace Holdings Inc's market cap, and Canadian Natural Resources Ltd. pays a 4.13% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CNQ | MEDP | |
|---|---|---|
Market Cap | $88.15B | $15.31B |
Sector | Energy | Technology |
52-Week High | $50.55 | $620.59 |
52-Week Low | $29.31 | $308.88 |
Enterprise Value | $99.38B | $14.78B |
Dividend Yield | 4.13% | — |
Signals from Pluang's Aura AI — not financial advice
CNQ trades at $43.05, up 2.97% today, with a bullish technical signal supported by moving averages and ADX. The stock shows strong fundamentals with a P/E of 11.8, net income margin of 24.5%, and consistent earnings beats in recent quarters. Recent news highlights its robust asset base and operational efficiency amid volatile oil markets. Cash flow remains positive, with 2025 net cash flow at $542 million.
Outlook is positive with analyst consensus strongly favoring Buy (75%), driven by valuation appeal and shareholder returns via dividends and buybacks. Key risks include oil price volatility and rising debt-to-asset ratio, which increased to 22.04% in 2024. The stock's proximity to its 52-week high suggests cautious optimism, but fundamentals support long-term growth potential.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Trailing returns across standard periods
Latest headlines on both assets
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →